Deidra Knauth
Payments from drug & device makers
Across 178 payments — averaging $78.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$10K
- AstraZeneca$851
- AbbVie$759
- Bayer$251
- Astellas Pharma US Inc$195
- GSK$178
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$6,75048%
- Travel & lodging$2,44417%
- Food & beverage$4,83934%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 42 | $10,476 |
| AstraZeneca | 26 | $851 |
| AbbVie | 37 | $759 |
| Bayer | 11 | $251 |
| Astellas Pharma US Inc | 4 | $195 |
| GSK | 9 | $178 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $160 |
| Exact Sciences | 3 | $151 |
| Novo Nordisk | 6 | $139 |
| Otsuka America Pharmaceutical, Inc. | 5 | $121 |
| Vifor Pharma, Inc. | 1 | $119 |
| Aurinia Pharma U.S., Inc. | 1 | $109 |
| Renalytix AI, Inc. | 6 | $102 |
| Lilly USA, LLC | 5 | $93 |
| Sumitomo Pharma America, Inc. | 4 | $79 |
| Phathom Pharmaceuticals, Inc. | 3 | $72 |
| Mallinckrodt Hospital Products Inc. | 2 | $62 |
| Boehringer Ingelheim | 2 | $44 |
| Merck | 1 | $21 |
| Shield Therapeutics Inc | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,033 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $55,379 |
| MounjaroTirzepatide | 29 | $41,012 |
| TrulicityDulaglutide | 31 | $38,497 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $27,412 |
| JanuviaSitagliptin Phosphate | 19 | $24,401 |
| JardianceEmpagliflozin | 24 | $20,869 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $17,757 |
| EliquisApixaban | 13 | $17,524 |
| FarxigaDapagliflozin Propanediol | 21 | $15,557 |
| LinzessLinaclotide | 14 | $15,483 |
| RybelsusSemaglutide | 11 | $12,750 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $2,393 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 85 | $2,124 |
| Gabapentin | 145 | $1,500 |
| Levothyroxine Sodium | 124 | $1,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $93 | $79,50860 claims |
| Novo NordiskOzempic, Rybelsus | $139 | $68,12953 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $851 | $33,31340 claims |
| GSKTrelegy Ellipta | $178 | $27,41239 claims |
| MerckJanuvia | $21 | $24,40119 claims |
| Boehringer IngelheimJardiance | $44 | $20,86924 claims |
| AbbVieLinzess | $759 | $15,48314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Troy
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.